New Zealand Approves MDMA Therapy For Severe PTSD, Becomes Second Country After Australia To Allow Use
New Zealand's medicines regulator has approved two psychiatrists to prescribe pharmaceutical-grade MDMA to people with severe post-traumatic stress disorder (PTSD), making the country only the second in the world to allow the drug for treating the condition. The approval by New Zealand's pharmaceutical regulatory body, Medsafe, follows Australia's decision in 2023 to permit the use of…
New Zealand's medicines regulator has authorized two psychiatrists to prescribe pharmaceutical-grade MDMA for treating severe post-traumatic stress disorder (PTSD). This makes New Zealand the second country, following Australia in 2023, to permit the use of the drug for this condition. Deputy Prime Minister David Seymour highlighted that PTSD can be devastating and challenging to treat, stating that MDMA can be highly effective through psychedelic-assisted therapy.
The approval by New Zealand's pharmaceutical regulatory body, Medsafe, aligns with Australia's decision and reflects the nation's commitment to expanding access to innovative treatments. PTSD is a mental health condition that can arise after experiencing or witnessing traumatic events, such as death, combat, or sexual assault. New Zealand's Ministry of Health emphasized that MDMA-assisted treatment would be administered in a controlled clinical setting under the supervision of an authorized psychiatrist, as part of a comprehensive treatment plan.
Patients receiving the therapy must be 18 years or older. Despite ongoing clinical trials in the US, pharmaceutical options for PTSD treatment remain limited to two antidepressants, with varying responses and a three-month dosing period.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
